Based on its cancer cell-specific expression and ability to modulate TNFα/ERK axis which can alter both cancer growth and metastatic potential, we hypothesized that MADD could also be a cancer-specific molecular target for ATC therapeutics. This evidence concerns the gene TNF and cancer.